ANIP vs AZN

Drug Manufacturers - Specialty & Generic · market cap $1.9b. 18% off the 52-week high of $99.50. Revenue growing +37% — in hypergrowth territory. PEG 0.48 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $110.00 (implying +35% upside).

ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.

Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.

Drug Manufacturers - General · market cap n/a. 19% off the 52-week high of $212.71. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $213.59 (implying +23% upside).

Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.

Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.